Immunotherapies based on the use of immune checkpoint inhibitors (ICI) target T-cell co-inhibitory signalings, namely, CTLA-4 and PD-1/PD-L1, and hence relieve their suppression of anti-tumor T-cell activity and prevent tumor immune evasion (Hargadon et al., 2018). The gene discussed is CTLA4; the disease is neoplasm.